HR+/HER2− breast cancer constitutes approximately 65–75% of all breast cancer cases worldwide. Although CDK4/6 inhibitors have substantially extended progression-free survival (PFS), up…
Announcing a new article publication in BIO Integration. The tumor vasculature, characterized by pathological angiogenesis and structural abnormalities,…